

Reference number(s)
1903-H

SPECIALTY QUANTITY LIMIT PROGRAM

TYKERB (lapatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tykerb (lapatinib) 250 mg tablets	180 tablets per 30 days	Breast cancer in combination with capecitabine: 1250 mg daily Breast cancer in combination with letrozole: 1500 mg daily

III. REFERENCE

1. Tykerb [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2017.